<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739828</url>
  </required_header>
  <id_info>
    <org_study_id>P15-692</org_study_id>
    <nct_id>NCT02739828</nct_id>
  </id_info>
  <brief_title>Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess quality of life (QoL), skin pain, work
      productivity/activity and health related problems in Swedish patients with moderate to severe
      HS before and after 6 months treatment with Adalimumab. The patients will be treated in
      accordance with normal routine clinical care.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a 10-question validated dermatologic disease questionnaire to measure quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol 5 Dimensions (EQ-5D)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The EQ-5D is a five dimensions generic questionnaire used to measure health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Skin Pain - numerical rating scale (NRS)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>Pain will be rated from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>HiSCR assesses HS inflammatory signs and symptoms that will determine clinical effectiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) measures work productivity and activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Impact Assessment (HSIA)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The Hidradenitis Suppurativa Impact Assessment (HSIA) is a disease specific questionnaire measuring the impact the patient experiences associated with HS.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Patients with Hidradenitis Suppurativa</arm_group_label>
    <description>Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab</description>
    <arm_group_label>Patients with Hidradenitis Suppurativa</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderate or severe Hidradenitis Suppurativa
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Hidradenitis Suppurativa

          -  Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)

          -  Willingness to sign and date a Patient Information/Informed Consent Form

        Exclusion Criteria:

          -  Prior biologic treatment discontinued &lt;6 months before the baseline visit

          -  Patient not able to understand the language of the provided patient questionnaires

          -  History of non-compliance with medication or a medical history that could enhance
             non-compliance with medication, as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallands Hospital Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blekinge Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Hospital</name>
      <address>
        <city>Skovde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Univ Sjukhuset</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Ume√•</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

